The EORTC 26053 (CANTON) trial indicated no benefit from concurrent TMZ but showed improved survival with adjuvant TMZ in IDH‐mutant glioma cases, necessitating further investigation into TMZ's optimal use.1, 17. The gene discussed is IDH1; the disease is glioma.